Is the role of rifaximin for ppx another unanswered (or semi-answered) question?
https://pubmed.ncbi.nlm.nih.gov/28994123/
https://pubmed.ncbi.nlm.nih.gov/27512927/
@ebtapper.bsky.social
@jasmohanbajaj.bsky.social
https://pubmed.ncbi.nlm.nih.gov/28994123/
https://pubmed.ncbi.nlm.nih.gov/27512927/
@ebtapper.bsky.social
@jasmohanbajaj.bsky.social
Comments
Might be answered in part by an ongoing/fully enrolled trial that is for HE prevention but enrolled mainly people with ascites
Found this digest, to your point. Seems like studies too small/flawed huh.
From Hepatology ‘21 “The Use of Rifaximin in Patients With Cirrhosis” also with @jasmohanbajaj.bsky.social
https://journals.lww.com/hep/fulltext/2021/09000/the_use_of_rifaximin_in_patients_with_cirrhosis.41.aspx